



**PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING AFTER ABDOMINAL SURGERY: APREPITANT/DEXAMETHASONE VS. MIRTAZAPINE/DEXAMETHASONE**

**Dr. Sheikh Rukun Uddin Ahmed\***

MBBS, MCPS, DA(BSMMU), MD(Anaesthesiology); Senior Consultant (Anaesthesia & Intensive Care Unit), BBMH, USTC, Foy's Lake, Chattogram, Bangladesh.

**\*Corresponding Author: Dr. Sheikh Rukun Uddin Ahmed**

MBBS, MCPS, DA(BSMMU), MD(Anaesthesiology); Senior Consultant (Anaesthesia & Intensive Care Unit), BBMH, USTC, Foy's Lake, Chattogram, Bangladesh.

Article Received on 16/09/2022

Article Revised on 05/10/2022

Article Accepted on 26/10/2022

**ABSTRACT**

**Introduction:** Patients having elective abdominal surgery under general anesthesia often have postoperative nausea and vomiting (PONV). Postoperative nausea and vomiting (PONV) may cause distress and dissatisfaction for the patient. PONV may also cause medical complications and delay discharge from hospital. This study investigated the effects of aprepitant/dexamethasone (A/D) combination versus mirtazapine/dexamethasone (M/D) combination vs dexamethasone (D) alone on PONV prophylaxis in individuals after abdominal surgery. **Objective:** In this study our main goal is to evaluate the outcome of aprepitant/dexamethasone (A/D) combination vs mirtazapine/ dexamethasone (M/D) combination vs dexamethasone (D) alone for prevention of PONV in individuals after abdominal surgery. **Method:** This was a cross-sectional study. This study was carried out at tertiary medical hospital from January 2021 to January 2022. Where a total of 150 patients scheduled for abdominal surgery were randomly allocated to receive 8 mg dexamethasone intravenous infusion (IVI) only in the D group or in addition to 80 mg aprepitant capsule in the A/D group or in addition to 30 mg mirtazapine tablet in the M/D group. In each 50 patients divided to each group. Assessment of PONV was carried out at 0–2 h (early) and 2–24 h (late). The primary outcome was the complete response 0-24 h after surgery. Collective PONV, postoperative pain, side effects and patient satisfaction score were considered as secondary outcomes. **Results:** During the study, majority were belonging to 41-50 years age group, 65% and 605 were male. In concordance to that, the intraoperative variables of duration of surgery and mean given intravascular fluid volume were comparable between groups. In the early postoperative period (0–2 h), there was a statistically significant difference between the A/D group and the D group in the number of vomiting episodes with comparable efficacy between the A/D and M/D groups. There were no statistically significant differences between the studied groups regarding nausea episodes, collective PONV, rescue antiemetic usage, and the number of patients exhibiting a complete response. pain score at (0–2 h) was significantly higher in the D group in comparison to the A/D and M/D groups with comparable efficacy between the A/D and M/D groups ( $P < 0.001$ ). The rescue analgesic doses were significantly higher in the D group compared to the A/D and M/D groups with statistically significant differences between the A/D and M/D groups ( $P < 0.001$ ). in addition, More patients in the A/D and M/D groups were satisfied with the PONV prevention protocol compared to the D group. **Conclusion:** The combination of aprepitant and dexamethasone, as well as mirtazapine and dexamethasone, has been proven to be more effective than dexamethasone alone in reducing postoperative nausea and vomiting in critically ill patients following abdominal surgery.

**KEYWORDS:** Abdominal Surgery, Aprepitant/dexamethasone, mirtazapine/dexamethasone.

**INTRODUCTION**

Patients may experience great suffering from postoperative nausea and vomiting (PONV), one of the most uncomfortable and prevalent adverse effects of anesthetics.<sup>[1]</sup> Furthermore, PONV might cause postoperative admission delays and increased healthcare expenses.<sup>[2]</sup>

It has been observed that without a prophylactic antiemetic, the incidence of PONV in patients undergoing different kinds of surgery ranges from 20% to 70%.<sup>[3,4,5]</sup>

Several variables, including age, sex, surgery type, and anesthetic-related ones, may contribute to PONV, which may cause significant pain among patients.<sup>[6,7,8]</sup> Preoperative volume loading and variables such as

obesity, a history of motion sickness, and/or a history of past postoperative emesis may potentially play a role in PONV.<sup>[9,10,11]</sup>

Concerns persist about what should be done to protect against PONV.<sup>[12]</sup> Although it has been shown to be cost-effective in high-risk individuals, global prophylaxis for PONV is not routinely advised.<sup>[13,14]</sup> Patients receiving procedures on the lower abdomen region are particularly at risk for PONV.

Dexamethasone is a glucocorticoid with a half-life of 36-48 hours, and it is used in a dose of 8-10 mg to prevent PONV in patients undergoing abdominal surgery due to its inexpensive cost and reduced adverse effects. It may function via antagonizing prostaglandins, preventing serotonin release in the stomach, and potentiating other antiemetics by sensitizing the pharmacological receptor.<sup>[11]</sup>

In this study our main goal is to evaluate the outcome of aprepitant/dexamethasone (A/D) combination vs mirtazapine/ dexamethasone (M/D) combination vs dexamethasone (D) alone for prevention of PONV in morbidly obese patients undergoing abdominal surgery.

#### OBJECTIVE

To assess the efficacy of aprepitant/dexamethasone (A/D) combination vs mirtazapine/ dexamethasone (M/D) combination vs dexamethasone (D) alone for prevention of PONV in morbidly obese patients undergoing abdominal surgery.

#### METHODOLOGY

This cross-sectional study was carried out at tertiary medical hospital from January 2021 to January 2022. Where a total of 150 patients scheduled for abdominal surgery were randomly allocated to receive 8 mg dexamethasone intravenous infusion (IVI) only in the D group or in addition to 80 mg aprepitant capsule in the A/D group or in addition to 30 mg mirtazapine tablet in the M/D group. In each 50 patients divided to each group. Assessment of PONV was carried out at 0-2 h (early) and 2-24 h (late). The primary outcome was the complete response 0-24 h after surgery. Collective PONV, postoperative pain, side effects and patient satisfaction score were considered as secondary outcomes.


#### RESULTS

In table-1 shows age distribution of the study group where majority were belonging to 41-50 years age group, 60%. Followed by 30% belong to >60 years group and 10% belong to 31-40 years age group. The following table is given below in detail.

**Table-1: Age distribution of the patients**

Age group	%
31-40 years	10%
41-50	60%
>60 years	30%

In figure-1n shows gender distribution of the study group where 60% were male and 40% were female. The following figure is given below in detail:



**Figure-1: Gender Distribution of the study group.**

In table-2 shows baseline status of the study group where in concordance to that, the intraoperative variables of duration of surgery and mean given intravascular fluid volume were comparable between groups. The following table is given below in detail.

**Table-2: Baseline status of the study group.**

	A/D group, %	M/D group, %	D group, %	P value
Comorbidities				
DM	24%	20%	16%	0.234
HTN	16%	17%	10%	
Smoking	46%	50%	44%	0.431
Motion sickness history	12%	15%	12%	0.541
History of PONV	11%	10%	18%	0.988
Operation duration, min	104.1	101.10	102.5	0.188
Intraoperative fluids, ml	1081.0	1098.2	1070.7	0.561

In table-3 shows post operative nausea and vomiting status where in the early postoperative period (0–2 h), there was a statistically significant difference between the A/D group and the D group in the number of vomiting episodes with comparable efficacy between the A/D and M/D groups. There were no statistically

significant differences between the studied groups regarding nausea episodes, collective PONV, rescue antiemetic usage, and the number of patients exhibiting a complete response. The following table is given below in detail.

**Table 3: Post operative nausea and vomiting status.**

Cases (0–2 h)	A/D group, %	M/D group, %	D group, %	P value
nausea episodes	14%	12%	18%	0.999
Grade of nausea				
I	0	10%	0%	0.231
II	31%	30%	44%	
III	69%	60%	56%	
vomiting episodes	0	12%	22%	0.5411
PONV	13%	22%	38%	1.112
Use of rescue antiemetic,	11%	10%	32%	2.321
Complete response	90%	88%	71%	<0.001*
cases (2–24 h)	A/D group, %	M/D group, %	D group, %	P value
nausea episodes	24%	12%	57%	<0.001*
Grade of nausea				
I	20%	55%	40%	<0.001*
II	50%	45%	60%	
III	30%			
vomiting episodes	4	11	36	<0.001*
PONV	27	25	91	<0.001*
Use of rescue antiemetic	12	13	71	<0.001*
Complete response	90	85	33	<0.001*
cases (0–24 h)	A/D group, %	M/D group, %	D group, %	P value
vomiting episodes	5	25	43	<0.001*
Grade of nausea				
I	12%			<0.001*
II	35%	48%	43%	
III	50%	51%	61%	
PONV	35	36	94	<0.001*
Use of rescue antiemetic	21	22	80	<0.001*
Complete response	80	77	21	<0.001*

In table-4 shows Postoperative findings among the groups where pain score at (0–2 h) was significantly higher in the D group in comparison to the A/D and M/D groups with comparable efficacy between the A/D and M/D groups ( $P < 0.001$ ). The rescue analgesic doses were significantly higher in the D group compared to the


A/D and M/D groups with statistically significant differences between the A/D and M/D groups ( $P < 0.001$ ). The following table is given below in detail.

**Table 4: Postoperative findings among the groups.**

Sedation	A/D group, %	M/D group, %	D group, %	P value
Ramsay sedation scale (preoperative)	1.6	2.4	1.3	$\wedge < 0.001^*$
Ramsay sedation scale (postoperative)	1.6	3.0	1.3	$\wedge < 0.001^*$
Postoperative pain and analgesia	A/D group, %	M/D group, %	D group, %	P value
Pain score 0–2 hour	2.0	2.2	2.7	$\wedge < 0.001^*$
Pain score 2–24 hour	2.4	3.8	4.4	$\wedge < 0.001^*$
Time to first rescue analgesia (ketorolac) (min)	89.4	77.9	53.5	$\wedge < 0.001^*$
Total dose of rescue analgesia (ketorolac), (mg) 0–24 hour	40.6	59.4	70.3	$\wedge < 0.001^*$

In figure-2 shows side effects where in all group Diarrhea and dizziness mostly commonly seen however apart from that, Incidences of the studied side effects

weren't statistically significant among the three groups. The following figure is given below in detail.

**Figure 2: Side effects STATUS.**

In table-5 shows Satisfaction score of the study group where More patients in the A/D and M/D groups were satisfied with the PONV prevention protocol compared

to the D group. The following table is given below in detail.

**Table 5: Satisfaction score of the study group.**

Satisfaction score	A/D group, %	M/D group, %	D group, %	P value
	5.2	1.6	2.9	$\wedge < 0.001^*$

## DISCUSSION

PONV after bariatric surgery can lead to dehydration, electrolyte imbalances, and possibly increase hospital length of stay. A standard regimen has not yet been identified.<sup>[7]</sup>

A multimodal antiemetic approach including 2 or more interventions is recommended.<sup>[8]</sup>

Doses of the aprepitant and dexamethasone combination were based on a previous study which revealed an efficient antiemetic effect in patients at high-risk of PONV from epidural fentanyl analgesia.<sup>[9]</sup> While doses of mirtazapine and dexamethasone combinations were based on research conducted by other study, who documented that premedication with this combination

significantly reduced PONV in patients undergoing gynecological procedures.<sup>[10]</sup>

In addition, the timing and method of administration of preemptive dexamethasone were based on research conducted by one study.<sup>[11]</sup>

Dexamethasone is recommended as a single perioperative injection of 8–14 mg to decrease PONV in the first 24 h after abdominal surgery.<sup>[12]</sup> It also has analgesic effects, improves respiratory parameters, decreases fatigue, low-cost drug, and promotes better recovery.<sup>[13]</sup> However, PONV prevention with 8 mg dexamethasone intravenously increased postoperative blood glucose values in nondiabetic and diabetic patients, irrespective of baseline blood glucose levels.<sup>[14]</sup>

In concordance with our study, other study concluded that a single preoperative dose of 80 mg aprepitant capsule significantly lowered PONV and pain medications 2–24 h after surgery in patients undergoing abdominal procedures.<sup>[11]</sup>

Other study documented the efficacy of adding oral 80 mg aprepitant to 4 mg ondansetron intravenously in the reduction of vomiting episodes at 72 h after laparoscopic bariatric surgery.<sup>[10]</sup>

Consistent with our study, other study reported that the combination of oral 80 mg aprepitant and 8 mg dexamethasone intravenously had a lower incidence of vomiting episodes from continuous epidural fentanyl analgesia at 24 h after elective knee osteoarthritis surgery.<sup>[12]</sup>

Other study concluded that a single dose of 40 mg aprepitant was equally effective to 8 mg ondansetron in 3 doses, 8 h apart, in preventing PONV, reducing the severity of nausea and the number of rescue antiemetics during the 24 h postoperative period in 125 women undergoing breast and thyroid surgeries.<sup>[13]</sup>

In addition, other demonstrated that aprepitant was superior to ondansetron in patients assigned to obtain a one preemptive dose of oral 40 mg aprepitant or oral 125 mg aprepitant, vs. 4 mg ondansetron intravenously.<sup>[14]</sup>

Over and above, other study found that a prepitant was noninferior to ondansetron in the prevention of vomiting over 0–24 h and there was no difference in peak nausea scores due to the fact that nausea is subjective and the implementation of different institutional protocols for administration of rescue therapy for nausea and vomiting episodes.<sup>[12]</sup>

In addition, one study reported that the combination of oral 40 mg aprepitant and 10 mg dexamethasone intravenously was more efficient than the combination of ondansetron and dexamethasone for the prevention of postoperative vomiting in adult patients scheduled for craniotomy under general anesthesia.<sup>[9]</sup>

Partially consistent with this study, Moon et al. documented a decreased nausea severity and increased rescue analgesics in the aprepitant group compared to the palonosetron group, 2 h after administration, in patients scheduled for laparoscopic gynecological surgeries under general anesthesia.<sup>[8]</sup>

Furthermore, in contrast to our study, one study reported that the combination of 8 mg dexamethasone intravenously and oral 40 mg aprepitant did not improve the complete response for PONV in comparison to the combination of 8 mg dexamethasone intravenously and 4 mg ondansetron intravenously in patients undergoing laparoscopic surgery.<sup>[6]</sup>

Results of this study were consistent with the other study who found that a single preoperative oral 30 mg mirtazapine decreased the incidence, delayed the onset and reduced the severity of nausea and vomiting after orthopedic surgery caused by intrathecal morphine in patients scheduled to undergo spinal anesthesia.<sup>[5]</sup>

Also, one report documented that oral 30 mg mirtazapine premedication significantly reduced preoperative anxiety and the incidence of postoperative early nausea and late vomiting in comparison with 16 mg ondansetron intravenously in 80 female patients undergoing breast surgery.<sup>[4]</sup>

## CONCLUSION

Aprepitant/dexamethasone and mirtazapine/dexamethasone combinations were shown to be more effective than dexamethasone alone in relieving postoperative nausea and vomiting in morbidly obese individuals undergoing abdominal surgery.

## REFERENCE

1. Lee DC, Kwak HJ, Kim HS, Choi SH, Lee JY. The preventative effect of ramosetron on postoperative nausea and vomiting after total thyroidectomy. *Korean J Anesthesiol*, 2011; 61: 154–8. [PMC free article] [PubMed] [Google Scholar]
2. Chatterjee S, Rudra A, Sengupta S. Current concepts in the management of postoperative nausea and vomiting. *Anesthesiol Res Pract* 2011. 2011 748031. [PMC free article] [PubMed] [Google Scholar]
3. Shinn HK, Lee MH, Moon SY, Hwang SI, Lee CS, Lim HK, et al. Post-operative nausea and vomiting after gynecologic laparoscopic surgery: Comparison between propofol and sevoflurane. *Korean J Anesthesiol*, 2011; 60: 36–40. [PMC free article] [PubMed] [Google Scholar]
4. Le TP, Gan TJ. Update on the management of postoperative nausea and vomiting and postdischarge nausea and vomiting in ambulatory surgery. *Anesthesiol Clin*, 2010; 28: 225–49. [PubMed] [Google Scholar]
5. Griffiths JD, Gyte GM, Paranjothy S, Brown HC, Broughton HK, Thomas J. Interventions for preventing nausea and vomiting in women undergoing regional anaesthesia for cesarean section. *Cochrane Database Syst Rev*, 2012; 9: CD007579. [PMC free article] [PubMed] [Google Scholar]
6. Safavi MR, Honarmand A. Low dose intravenous midazolam for prevention of PONV, in lower abdominal surgery-preoperative vs intraoperative administration. *Middle East J Anesthesiol*, 2009; 20: 75–81. [PubMed] [Google Scholar]
7. Honarmand A, Safavi M, Khalili G, Mohammadnejad F. Prophylactic administration of haloperidol plus midazolam reduces postoperative nausea and vomiting better than using each drug alone in patients undergoing middle ear surgery.

- Saudi J Anaesth, 2012; 6: 145–51. [PMC free article] [PubMed] [Google Scholar]
8. Jabalameli M, Honarmand A, Safavi M, Chitsaz M. Treatment of postoperative nausea and vomiting after spinal anesthesia for cesarean delivery: A randomized, double-blinded comparison of midazolam, ondansetron, and a combination. *Adv Biomed Res*, 2012; 1: 2. [PMC free article] [PubMed] [Google Scholar]
  9. Safavi M, Honarmand A, Habibabady MR, Baraty S, Aghadavoudi O. Assessing intravenous ketamine and intravenous dexamethasone separately and in combination for early oral intake, vomiting and postoperative pain relief in children following tonsillectomy. *Med Arh*, 2012; 66: 111–5. [PubMed] [Google Scholar]
  10. Heidari SM, Talakoub R, Yaraghi Z. Comparing the preventive effect of midazolam and midazolam-dexamethasone on postoperative nausea and vomiting in elective middle ear surgery. *Adv Biomed Res*, 2012; 1: 9. [PMC free article] [PubMed] [Google Scholar]
  11. Heidari SM, Saghaei M, Shafiee Z. Effect of preoperative volume loading on the intraoperative variability of blood pressure and postoperative nausea and vomiting. *Med Arh*, 2012; 66: 94–6. [PubMed] [Google Scholar]
  12. Heidari SM, Saryazdi H, Saghaei M. Effect of intravenous midazolam premedication on postoperative nausea and vomiting after cholecystectomy. *Acta Anaesthesiol Taiwan*, 2004; 42: 77–80. [PubMed] [Google Scholar]
  13. Diemunsch P, Diemunsch AM. Economics of antiemetics. *Curr Opin Anaesthesiol*, 2002; 15: 233–7. [PubMed] [Google Scholar]
  14. Klaiman P, Sternfeld M, Deeb Z, Roth Y, Golan A, Ezri T, et al. Magnetic acupressure for management of postoperative nausea and vomiting: A preliminary study. *Minerva Anesthesiol*, 2008; 74: 635–42. [PubMed] [Google Scholar]